All GLP-1 medications from licensed 503A compounding pharmacies Browse Products

BPC-157 Dosage Guide: Protocols & Safety 2026

Complete BPC-157 dosage guide with protocols for oral, injection, and nasal. Dosing by body weight, cycling schedules, and reconstitution instructions.

By Emily Rodriguez, RDN, CSSD|Reviewed by Dr. David Kim, MD, FACE||

Medically Reviewed

Written by Emily Rodriguez, RDN, CSSD · Reviewed by Dr. David Kim, MD, FACE

BPC-157 Dosage Guide: Protocols & Safety 2026 custom 2026 header image for Peptide Therapy
Custom header image for BPC-157 Dosage Guide: Protocols & Safety 2026, Peptide Therapy, and better treatment decision-making.
In This Article

This article is part of our Peptide Therapy collection. See also: GLP-1 Guides | Provider Comparisons

Search and AI answer brief

Practical answer: BPC-157 Dosage Guide: Protocols & Safety 2026

Complete BPC-157 dosage guide with protocols for oral, injection, and nasal. Dosing by body weight, cycling schedules, and reconstitution instructions.

Short answer

Complete BPC-157 dosage guide with protocols for oral, injection, and nasal. Dosing by body weight, cycling schedules, and reconstitution instructions.

Search intent

This page answers a specific Peptide Therapy question rather than a generic overview.

What to verify

semaglutide, tirzepatide, peptide evidence quality, safety and contraindications

How to use it

Use this information to prepare sharper questions for a licensed provider.

BPC-157 doses in research typically range from 200 to 800 mcg per day, given once or twice daily by subcutaneous injection or oral capsule. Animal studies most often use 10 mcg/kg of body weight as a reference. There is no standardized human protocol, so a physician should set your dose based on your condition, body weight, route, and goals. This page is educational. BPC-157 is not FDA-approved

Quick answer: What is the standard BPC-157 dose? Research uses 200 to 800 mcg per day, with 10 mcg/kg as the common animal reference, which scales to roughly 200 to 500 mcg/day in humans. The most common starting protocol is 250 mcg twice daily. No official human dosing standard exists, so doses should be set with a physician. BPC-157 is a research peptide and is not FDA-approved.

What is BPC-157?

BPC-157 (Body Protection Compound-157) is a synthetic 15-amino-acid peptide derived from a protein found in human gastric juice. It has been studied in hundreds of preclinical experiments for tissue repair, gut health, and recovery. Getting the dose right matters: too little may do nothing, while more than needed wastes product without clearly improving results. Animal safety data has not identified a toxic dose, but that does not replace physician guidance.

What is the standard BPC-157 dosage?

The standard research range is 200 to 800 mcg per day. The most common starting point is 250 mcg twice daily, totaling 500 mcg per day. Lower doses suit general wellness, while higher doses are used for active injuries.

GoalDaily doseFrequencyRouteDuration
General wellness200 to 300 mcgOnce dailySubcutaneous4 to 6 weeks
Moderate injury recovery300 to 500 mcgOnce or twice dailySubcutaneous near injury4 to 8 weeks
Significant tissue repair500 to 800 mcgTwice dailySubcutaneous near injury6 to 12 weeks
Gut health250 to 500 mcgOnce or twice dailyOral capsule4 to 8 weeks
Tendon or ligament300 to 500 mcgTwice dailySubcutaneous near tendon6 to 10 weeks

These ranges are commonly discussed protocols in physician-supervised peptide therapy, not standardized medical guidelines.

How does BPC-157 dosing work in research?

In the literature, BPC-157 doses are reported in micrograms per kilogram of body weight. The most studied dose in rodent models is 10 mcg/kg, with a studied range of about 1 to 50 mcg/kg. Animal doses do not translate directly to humans. Using the FDA's body-surface-area conversion, a 10 mcg/kg rat dose maps to roughly 1.6 mcg/kg in a human, but most practitioners use higher doses based on clinical experience. This gap is exactly why a physician, not a research paper, should set your dose.

Check your GLP-1 eligibility

Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.

Try the BMI Calculator →
Dose (mcg/kg)Observed effectStudy context
1 mcg/kgMild protective effectsGastric ulcer models
10 mcg/kgMost consistent therapeutic effectsTendon, gut, muscle, nerve injury models
50 mcg/kgNo added benefit over 10 mcg/kg in most modelsHigh-dose studies

How do you dose BPC-157 by body weight?

Some physicians adapt the 10 mcg/kg model to body weight. Because that figure comes from rodent research, many start patients at the low end (about 5 mcg/kg or a flat 250 mcg) and adjust over one to two weeks.

Body weightLow dose (5 mcg/kg)Standard (10 mcg/kg)High (15 mcg/kg)
140 lbs (64 kg)~320 mcg~640 mcg~960 mcg
180 lbs (82 kg)~410 mcg~820 mcg~1230 mcg
220 lbs (100 kg)~500 mcg~1000 mcg~1500 mcg

What are the tissue-specific dosing protocols?

Practitioners often tailor dose, route, and injection site to the target tissue.

  • Tendon and ligament: 300 to 500 mcg twice daily, subcutaneous near the tendon, 6 to 10 weeks. Peritendinous injection targets tissue with poor blood supply.
  • Muscle: 250 to 500 mcg once or twice daily, subcutaneous near the muscle, 4 to 8 weeks.
  • Gut: 250 to 500 mcg once or twice daily, oral on an empty stomach, 4 to 8 weeks. BPC-157 is acid-stable, so oral delivery is viable.
  • Joint and cartilage: 250 to 500 mcg once or twice daily, subcutaneous near the joint, 8 to 12 weeks.
  • Nerve: 300 to 500 mcg once or twice daily, subcutaneous, 8 to 12 weeks. Nerve repair is among the slowest.

How do you dose by administration route?

RouteBioavailabilityBest forConvenience
SubcutaneousHighMusculoskeletal and systemicNeeds injection technique
IntramuscularHighDeep muscle injuriesNeeds injection technique
Oral (capsule)Moderate, acid-stableGut and GI conditionsEasy

Subcutaneous is the most common method, with most protocols at 250 to 500 mcg per injection. For local effects, many practitioners inject near the target area. For systemic effects, the abdomen is standard. Oral dosing is preferred for gut conditions and is taken on an empty stomach.

How do you reconstitute BPC-157?

BPC-157 usually comes as a freeze-dried powder that must be reconstituted with bacteriostatic water before use.

  1. Confirm the amount in the vial (commonly 5 mg or 10 mg).
  2. Gather BAC water, alcohol swabs, and insulin syringes.
  3. Wipe both vial tops.
  4. Draw the desired BAC water volume.
  5. Let the water run down the inside wall, do not spray onto the powder.
  6. Swirl gently, do not shake, until clear.
  7. Refrigerate at 36 to 46 F and use within 28 days.
Vial sizeBAC water addedConcentration250 mcg500 mcg
5 mg2 mL2,500 mcg/mL0.10 mL (10 units)0.20 mL (20 units)
10 mg2 mL5,000 mcg/mL0.05 mL (5 units)0.10 mL (10 units)

Adding 2 mL of BAC water to a 5 mg vial (2,500 mcg/mL) is a popular choice for easy measurement. Never freeze the reconstituted solution, protect it from light, and discard if it turns cloudy or shows particles.

How long should a BPC-157 cycle last?

Most physician-supervised protocols use cycles rather than continuous use: 4 weeks for mild issues, 6 to 8 weeks for moderate injuries or gut healing, and 8 to 12 weeks for severe cases. A 2 to 4 week break follows most cycles. There is no established research on long-term, uninterrupted human use, so cycling is the prudent approach.

Safety considerations

BPC-157 has shown a strong safety profile in animal studies with no toxic dose identified, but dosing should always involve a physician because animal data does not translate directly, individual factors affect response, and product quality varies. Use only pharmaceutical-grade material from a licensed source. BPC-157 should not be used by people who are pregnant or breastfeeding, who have active cancer (it promotes angiogenesis), who are under 18, or who have a known allergy to it.

A note on FormBlends and BPC-157

BPC-157 is not FDA-approved. FormBlends provides compounded semaglutide and tirzepatide for weight management. This guide is educational, and any BPC-157 protocol should be set and supervised by a licensed physician who can tailor the dose and verify product quality.

Frequently asked questions

What is the standard BPC-157 dosage? There is no official standard. Research references 10 mcg/kg in animals, and human practice typically uses 200 to 800 mcg per day. A physician should determine your dose.

How often should I take BPC-157? Once or twice daily. Once daily suits lower doses and general wellness; twice daily is common for active injuries.

Can I take too much BPC-157? Animal studies have not found a toxic dose, but more than needed does not improve results and wastes product.

Should I inject near the injury or in my stomach? For musculoskeletal injuries, inject subcutaneously near the site. For gut issues, oral dosing targets the GI tract. For systemic effects, the abdomen is standard.

How much bacteriostatic water do I add? For a 5 mg vial, 2 mL creates 2,500 mcg/mL, a popular ratio for easy dosing.

Does BPC-157 need refrigeration? Lyophilized powder is stable at room temperature. After reconstitution it must be refrigerated and used within 28 days.

Can I stack BPC-157 with TB-500? That is the most common injury-recovery stack, but any stacking should be designed and supervised by a physician.

Is BPC-157 FDA-approved? No. It is a research peptide and is not FDA-approved for any condition. FormBlends does not sell it.

Sources

  • BPC-157 dosage guide 2026 (Peptides Insider): https://peptidesinsider.com/peptides/bpc-157/dosage
  • BPC-157 dosage protocols (PeptideWiki): https://peptidewiki.co/guides/dosage-guides/bpc-157-dosage-guide
  • BPC-157 dosing, reconstitution, safety 2026: https://www.peptidedosingprotocols.com/protocol/bpc-157
  • Sikiric P, et al. Stable gastric pentadecapeptide BPC 157. Curr Pharm Des. 2011;17(16):1612-1632.
  • Nair AB, Jacob S. Dose conversion between animals and human. J Basic Clin Pharm. 2016;7(2):27-31.

Evidence standard

How this page was source-checked

Editorial policy

FormBlends does not claim an individual clinician byline unless a named reviewer is available. For this page, the editorial team checks medical and regulatory claims against primary sources, clinical trials, public datasets, and regulator guidance.

PubMed evidence trail

Research sources used to frame this page

For BPC-157 Dosage Guide: Protocols & Safety 2026, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.

Peptide decision path

Move from research interest to supervised review

Direct answer

BPC-157 Dosage Guide: Protocols & Safety 2026 should be evaluated through research status, legal access, source quality, safety context, and clinician oversight rather than a shortcut purchase decision.

Evidence check

Useful peptide pages should separate human data, animal research, mechanistic evidence, and marketing claims.

Safety check

Peptides can vary by legal status, compounding pathway, purity testing, patient history, and interaction risk.

Next step

If the topic still fits your goal after reading, the get-started flow should collect the clinical context needed for provider review.

FormBlends Editorial Context

Reviewed May 14, 2026

Complete BPC-157 dosage guide with protocols for oral, injection, and nasal. Dosing by body weight, cycling schedules, and reconstitution instructions. Use "BPC-157 Dosage Guide: Protocols & Safety 2026" to make the conversation more specific before you choose a provider, product, or next step. The page leans into safety and side-effect planning and the details behind BPC-157, dosing, safety and pharmacy quality. Because this article has 16 major sections, scan the headings first and then use the FAQ or summary sections to pressure-test the answer. The safest takeaway is a better checklist for clinician review, not a do-it-yourself medical decision.

  • Confirm whether the page is discussing an FDA-approved use, a compounded option, or research-only context.
  • Ask a licensed clinician how the evidence applies to your health history, medications, labs, and side-effect risk.
  • Verify the pharmacy pathway, certificate of analysis, sterility testing, and clinician oversight before trusting a source.

Original tools and data

Use the FormBlends research stack

These assets are built to be useful beyond a single article: shareable data pages, calculators, provider comparisons, and safety checks that give Google and readers something original to crawl.

Editorial refresh

Practical 2026 note for BPC

This update makes BPC more specific by tying semaglutide, tirzepatide, BPC-157, safety signals, bpc, 157 to the page's original clinical, cost, access, or comparison angle.

The goal is to make the article more useful for people who already know the headline question and need page-level specifics, not another interchangeable peptide therapy summary.

For 2026 review, the content emphasizes current verification, treatment fit, and patient-safety questions that can be discussed with a qualified provider.

BPC custom 2026 image for peptide therapy on FormBlends

Custom 2026 image for BPC, peptide therapy, and better treatment decision-making.

Image description: Unique image for this page covering BPC, peptide therapy, safety, cost, provider selection, and patient decision-making.

Download the Peptide Quick Reference Card

A printable 2-page reference covering popular peptides, dosing ranges, stacking protocols, and storage.

Free download. We'll also send helpful GLP-1 guides to your inbox. Unsubscribe anytime.

Medical Disclaimer: This content is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication or treatment. FormBlends articles are source-checked against medical and regulatory references, but they are not a substitute for a personal medical consultation.

Written by Emily Rodriguez, RDN, CSSD

Registered Dietitian. This article was researched against primary regulatory, trial, prescribing, and manufacturer sources where available. Reviewed by Dr. David Kim, MD, FACE for medical accuracy, sourcing, and patient-safety framing.

Ready to get started?

Provider-reviewed GLP-1 and peptide therapy, delivered to your door.

Start Your Consultation

Ready to Start Your Weight Loss Journey?

Get a free medical consultation with a licensed provider. Compounded GLP-1 medications starting at $99/month with free shipping.

Next Best Reads

Free Tools

Provider-informed calculators to support your weight loss journey.